Philips promotes special report and hosts session on early detection and diagnosis of non-communicable diseases during United Nations General Assembly

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Algemeen advies 26/09/2018 09:26
. Comprehensive report from Philips and Devex highlights the role of early detection and diagnosis in the global fight against non-communicable diseases
•Side-session to the WEF Sustainable Development Impact Summit deep dives into how non-communicable disease challenges can be confronted

Amsterdam, the Netherlands and New York, US – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced publication of a special report on early detection of non-communicable diseases (NCDs) as a critical link in effective NCD management. Researched and written by Devex [1], the report highlights the role that early detection and diagnosis plays in the global effort to combat widespread NCDs such as cardiovascular disease, lung disease, cancer and diabetes. Publication of the report coincides with the 73rd Session of the United Nations General Assembly (UNGA 73) in New York, US, during which the UN is staging its third high-level meeting on the prevention and control of NCDs.

NCDs are a truly global problem, impacting both developed and developing countries. It is currently estimated that around 41 million people a year die from NCDs, equivalent to more than 70% of all deaths globally, with developing countries in fact being impacted most due to poor access to healthcare. The NCD challenge is addressed in the United Nations 2030 Agenda for Sustainable Development, which explicitly states that reducing the death toll due to NCDs should be a sustainable development priority for all countries, while the World Health Assembly has endorsed the WHO Global Action Plan for the Prevention and Control of NCDs, which aims to reduce premature mortality from NCDs by 25% by 2025.

To produce the new report, titled ‘Early Detection: a Critical Link for Effective NCD Management’, Devex interviewed more than a dozen key opinion leaders and polled more than 1,200 health professionals. Of those surveyed, 98% agreed that addressing NCDs is a critical component of achieving UN Sustainable Development Goal #3 ‘Ensure healthy lives and promote well-being for all at all ages’, and that a strong primary healthcare system is one of the best ways to prevent NCDs and detect patients who suffer from them. Almost half of the respondents regarded early detection and diagnosis, together with education on preventative behavior change, as ways in which primary care systems could contribute to the fight against NCDs. Yet despite this, the majority expressed the opinion that prevention and diagnosis are currently underprioritized and underinvested.

“For those affected by NCDs, early diagnosis and treatment remain the best way to reduce patient suffering and mitigate healthcare costs,” said Frans van Houten, CEO of Royal Philips. However, many countries do not have the health facilities, clinical workforce or technology to support prevention, diagnosis and treatment, which is why Philips is committed to help. The Philips Community Life Center model is one way in which we’re working with communities on new business models to build facilities, train healthcare workers and bring diagnostic innovations, such as our portable Lumify tele-ultrasound solution, within people’s reach.”

As part of its mission to improve the lives of 3 billion people a year by 2025, Philips is committed to helping enable high quality universal health coverage (UHC). In Ethiopia, for example, Philips has signed a seven-year agreement with the government to build Ethiopia’s first specialized Cardiac Care Center to address the critical shortage of cardiology services in the country. In Colombia, the Philips Foundation [2] is collaborating with Liga Contra el Cancer to implement a prostate cancer education and diagnosis program that will improve the lives of 1,600 males.

Special side-session on NCDs
During this year’s United Nations General Assembly week, Philips and Devex, in collaboration with the World Economic Forum, will also host a special side-session to the Sustainable Development Impact Summit. This side-session, which takes place on Wednesday, September 26, from 9:30 - 11:00 AM at Convene, Union Square Hub, 730 Third Ave., New York City, will deep dive into how NCD challenges can be confronted by including early diagnosis in future plans for prevention and treatment. The discussion will also link to the wider debate on universal health coverage and the importance of primary health care in providing the holistic patient-centered focus needed to combat NCDs at local level.

[1] Devex is the leading social enterprise and media platform for the global development community
[2] The Philips Foundation is the Corporate & Social Responsibility (CSR) foundation set up by Royal Philips as part of its mission to improve the lives of 3 billion people a year by 2025. Philips Foundation’s mission is to reduce healthcare inequality by providing access to quality healthcare for disadvantaged communities

September 26, 2018

Philips and global healthcare leaders develop innovative resuscitation device to help reduce neonatal mortality

Amsterdam, the Netherlands and New York, NY – On the occasion of the 73rd Session of the United Nations General Assembly (UNGA 73), Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful development of the ‘Augmented Infant Resuscitator (AIR)’ – an add-on device for conventional neonatal bag-valve-mask (BVM) resuscitators that helps care givers to effectively resuscitate asphyxiated newborn babies. Developed in collaboration with the Consortium for Affordable Medical Technologies (CAMTech) at Massachusetts General Hospital Global Health, the Philips Augmented Infant Resuscitator aims to reduce neonatal mortality, especially in parts of the world that are underserved in terms of healthcare. It is expected to be available in limited volume in selected markets prior to scaling up availability in low- and middle-income countries.

Birth asphyxia’s global impact
Birth asphyxia is a medical condition caused by prolonged deprivation of oxygen to a newborn during the birth process, resulting in damage to vital organs, usually the baby’s brain. Globally, birth asphyxia causes more than 800,000 neonatal deaths annually, and over one million potentially preventable reported stillbirths [1]. Effective resuscitation could reduce birth asphyxia related neonatal deaths by 30 percent, and deaths from prematurity by 10 percent [2]. However, one-in-five trained healthcare professionals fail to perform the resuscitation technique correctly, and those that do often experience a rapid decline in proficiency [3].

Effective resuscitation through innovation
The AIR device is an innovative add-on that is compatible with virtually all existing manual bag-valve-mask resuscitators. It has the potential to significantly improve the initial training and ongoing practice of bag-valve-mask resuscitation skills. The device measures ventilation flow and pressure to monitor the quality of ventilation, and provides intuitive visual feedback on common ventilation errors, including inadequate face-mask seal, obstructed airway, incorrect ventilation rate, and harsh breaths that can damage the baby’s airways. Any one of these mistakes may result in death or permanent neurological injury. The AIR also records performance for future feedback, improving the training of healthcare professionals by identifying persistent gaps in technique.

“At Philips, we aim to improve people’s health through meaningful innovations,” said Arman Voskerchyan, Business Leader for Therapeutic Care at Philips. “Our mission is to improve the lives of three billion people a year by 2025. By combining our expertise in respiratory care and resuscitation with the strengths of global health innovators like the AIR team at CAMTech, we aim to drive and scale innovative solutions that bridge societal divides in healthcare to reach underserved populations, and thereby addressing the United Nations Sustainable Development Goal 3.”

Recent history of AIR
Dr. Kristian Olson, Director of CAMTech at Massachusetts General Hospital Global Health, Dr. Data Santorino, CAMTech Uganda Country Manager, and Dr. Kevin Cedrone, a lecturer at the Massachusetts Institute of Technology (MIT), first created the AIR device prototype in 2012 at a CAMTech Hack-a-thon with MIT at Massachusetts General Hospital. After receiving an initial grant from CAMTech in early 2013, further development and testing of the AIR device was supported by Saving Lives at Birth (SLAB) – A Grand Challenge for Development partners. In late 2016, the AIR team completed a multi-center randomized trial of 270 birth attendants in both Uganda and the US, details of which will be presented in a future publication.

Next steps
Since 2016, Philips and the AIR team have further developed the device. Philips recently obtained a license for the relevant Intellectual Property owned by Partners Healthcare and Mbarara University of Science and Technology, to commercialize and scale the Augmented Infant Resuscitator device. CAMTech will continue to gather new impact, usability and cost-effectiveness data through a multi-country trial in India, Uganda and Ghana, for which Philips will provide CAMTech with more than 200 engineering samples.

[2] Wall SN, Lee AC, Carlo W, Goldenberg R, Niermeyer S, Darmstadt GL, et al. Reducing intrapartum-related neonatal deaths in low- and middle-income countries-what works? Semin Perinatol 2010 Dec; 34(6):395-407.
[3] Patel J, Posencheg M, Ades A. Proficiency and retention of neonatal resuscitation skills by pediatric residents. Pediatrics 2012 Sep; 130(3):515-521.

Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord

Copyrights © 2000 by all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.